NASDAQ:ACRV · NASDAQ Global Market
+$0.05 today
Vol 0.26M · Avg 0.60M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Management quality matters because capital allocation choices determine how much of Acrivon Therapeutics, Inc. Common Stock earnings power becomes long-term shareholder value. Use this page to compare ACRV returns on capital, executive context, insider transactions, ownership signals, and growth trends against peers, then decide whether leadership appears disciplined, aligned, and capable of compounding through changing market conditions.
Return Metrics
ROE, ROIC & ROA over time
ROE
-69.2%
avg -8.6%
ROIC
-73.0%
avg -67.4%
ROA
-60.1%
avg -70.0%
Analysis
ROA is currently the strongest return metric at -60.1% versus its period average of -70.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Peter Blume-Jensen | Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer | $1.13M | — | 63 | $2.25M | 7.12% |
Kristina Masson | Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer & Director | $851,720.00 | — | 46 | $317,246.00 | 1.01% |
Eric J. Devroe | Chief Operating Officer | $784,797.00 | — | 47 | $146,953.00 | 0.47% |
Mary-Alice Miller | Chief Legal Officer & Corporate Secretary | $587,108.00 | — | 52 | $82,767.00 | 0.26% |
Erick Gamelin | Chief Development Officer | $480,723.00 | — | 68 | $52,992.00 | 0.17% |
Adam D. Levy | Chief Financial Officer & Principal Financial Officer | — | — | 60 | $67,150.00 | 0.21% |
Jesper V. Olsen | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board | — | — | — | — | — |
Bruce Close | Vice President of Quality & Compliance | — | — | — | — | — |
Joon Jung | Vice President & Head of Data Science | — | — | — | — | — |
Katharine Peterson | Vice President of Finance & Accounting | — | — | — | $18,134.00 | 0.06% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$114,341.39
Sells
0
$0.00
Net Sentiment
+$114,341.39
Net buying
Most Active
Blume-Jensen Peter
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Jan 14, 2026 | Blume-Jensen Peter Direct | Buy | 49.0K | $1.68 | $82,124.00 | |
| Jan 14, 2026 | Levy Adam D. Direct | Buy | 8.8K | $1.70 | $14,999.39 | |
| Jan 13, 2026 | Devroe Eric Direct | Buy | 10.0K | $1.72 | $17,218.00 |
Analysis
Insiders reported 3 buys worth $114,341.39 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $114,341.39. Blume-Jensen Peter was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$496.47M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$172.36M
Immunic, Inc.
NASDAQ:IMUX
$148.72M
Vaxart, Inc.
NASDAQ:VXRT
$125.60M
Biomea Fusion, Inc.
NASDAQ:BMEA
$73.18M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$64.53M
Cibus, Inc.
NASDAQ:CBUS
$62.32M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$56.25M
aTyr Pharma, Inc.
NASDAQ:ATYR
$52.66M
Who manages ACRV?
Acrivon Therapeutics, Inc. Common Stock (ACRV) lists 10 active executives. The top listed executive is Adam D. Levy, Chief Financial Officer & Principal Financial Officer.
Are ACRV insiders buying or selling?
Recent insider activity shows net buying of $66.14M.
Explore More
Continue the stock analysis
Jump to another research area for this company.